Roth Capital Lifts Earnings Estimates for LeMaitre Vascular

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Investment analysts at Roth Capital boosted their FY2024 earnings estimates for LeMaitre Vascular in a report issued on Thursday, October 31st. Roth Capital analyst J. Wittes now expects that the medical instruments supplier will post earnings of $1.96 per share for the year, up from their previous forecast of $1.81. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.86 per share. Roth Capital also issued estimates for LeMaitre Vascular’s Q3 2025 earnings at $0.51 EPS, Q4 2025 earnings at $0.53 EPS, FY2025 earnings at $2.06 EPS, FY2026 earnings at $2.32 EPS and FY2027 earnings at $2.54 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.39%. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.33 earnings per share.

A number of other research firms have also weighed in on LMAT. Barrington Research upped their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective for the company. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Oppenheimer reiterated an “outperform” rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday. Finally, Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Price Performance

LMAT opened at $96.35 on Monday. LeMaitre Vascular has a fifty-two week low of $47.72 and a fifty-two week high of $101.67. The firm has a market capitalization of $2.16 billion, a PE ratio of 52.65, a P/E/G ratio of 2.32 and a beta of 0.89. The company’s 50-day moving average is $89.70 and its 200 day moving average is $83.49.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds have recently bought and sold shares of the business. CANADA LIFE ASSURANCE Co raised its holdings in shares of LeMaitre Vascular by 44.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after purchasing an additional 6,875 shares during the last quarter. Quantbot Technologies LP lifted its position in LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after purchasing an additional 6,669 shares during the last quarter. Vanguard Group Inc. lifted its position in LeMaitre Vascular by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after purchasing an additional 38,303 shares during the last quarter. Quadrature Capital Ltd lifted its position in LeMaitre Vascular by 129.4% during the first quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock valued at $1,484,000 after purchasing an additional 12,654 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after acquiring an additional 47,218 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.